TEM · Tempus Ai, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q4 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $348.12M | - | $334.21M | $314.63M | $145.82M | - | $180.93M | $165.97M | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $48.24M | - | $44.96M | $41.62M | $24.34M | - | $27.35M | $22.17M | - | - |
| SG&A | $212.59M | - | $187.89M | $180.71M | $79.56M | - | $101.43M | $71.19M | - | - |
| Total Operating Expenses | $432.83M | - | $395.20M | $376.41M | $199.09M | - | $234.54M | $177.56M | - | - |
| D&A | $7.42M | - | $8.12M | $8.35M | $6.27M | - | $6.79M | $6.42M | - | - |
| Operating Income | ($84.71M) | - | ($61.00M) | ($61.77M) | ($53.27M) | - | ($53.62M) | ($533.49M) | - | - |
| Interest Expense | $14.34M | - | $15.40M | $21.58M | $13.24M | - | $13.76M | $11.71M | - | - |
| Income Tax | ($62.0K) | - | $38.0K | $212.0K | $11.0K | - | - | - | - | - |
| Net Income | ($125.92M) | - | ($79.98M) | ($42.84M) | ($64.74M) | - | ($75.84M) | ($552.21M) | - | - |
| EPS - Basic | ($0.70) | - | ($0.46) | ($0.25) | ($1.47) | - | ($1.03) | ($6.86) | - | - |
| EPS - Diluted | ($0.71) | - | ($0.46) | ($0.25) | ($1.47) | - | ($0.46) | ($6.86) | - | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q4 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $521.17M | $604.79M | $655.92M | $186.31M | $79.94M | $340.95M | $388.01M | $165.77M | - | $302.94M |
| Accounts Receivable | $308.60M | $311.17M | $283.63M | $266.28M | $262.61M | $154.82M | $145.62M | $118.11M | - | - |
| Inventory | $51.83M | $51.72M | $54.98M | $47.60M | $50.48M | $38.39M | $36.14M | $32.69M | $27.30M | - |
| Accounts Payable | $41.02M | $81.99M | $59.55M | $79.32M | $88.73M | $53.80M | $49.03M | $28.65M | - | - |
| Current Assets | $1.05B | $1.17B | $1.15B | $644.20M | $573.97M | $667.60M | $679.41M | $350.33M | - | - |
| Total Assets | $2.14B | $2.27B | $2.28B | $1.63B | $1.54B | $926.12M | $971.73M | $864.61M | - | - |
| Current Liabilities | $317.96M | $372.39M | $350.03M | $418.16M | $336.47M | $291.07M | $252.62M | $232.63M | - | - |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $1.72B | $1.78B | $1.77B | $1.32B | $1.22B | $869.78M | $918.00M | $840.67M | - | - |
| Stockholders' Equity | $416.40M | $491.33M | $507.82M | $309.56M | $326.19M | $56.34M | $53.73M | ($1.19B) | - | - |
| Retained Earnings | ($2.52B) | ($2.40B) | ($2.34B) | ($2.26B) | ($2.22B) | ($2.15B) | ($2.14B) | ($2.06B) | - | - |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q4 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($73.28M) | - | - | - | ($101.38M) | - | - | - | - | - |
| Investing Cash Flow | ($10.07M) | - | - | - | $16.99M | - | - | - | - | - |
| Financing Cash Flow | ($271.0K) | - | - | - | ($1.38M) | - | - | - | - | - |
| CapEx | $8.20M | - | - | - | $6.11M | - | - | - | - | - |
| Free Cash Flow | ($81.48M) | - | - | - | ($107.49M) | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q4 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | -24.3% | - | -18.3% | -19.6% | -36.5% | - | -29.6% | -321.4% | - | - |
| EBITDA margin | -22.2% | - | -15.8% | -17.0% | -32.2% | - | -25.9% | -317.6% | - | - |
| Net margin | -36.2% | - | -23.9% | -13.6% | -44.4% | - | -41.9% | -332.7% | - | - |
| Free cash flow margin | -23.4% | - | - | - | -73.7% | - | - | - | - | - |
| FCF / Net income | 0.65 | - | - | - | 1.66 | - | - | - | - | - |
| R&D / Revenue | 13.9% | - | 13.5% | 13.2% | 16.7% | - | 15.1% | 13.4% | - | - |
| SG&A / Revenue | 61.1% | - | 56.2% | 57.4% | 54.6% | - | 56.1% | 42.9% | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -5.9% | - | -3.5% | -2.6% | -4.2% | - | -7.8% | -63.9% | - | - |
| Return on equity | -30.2% | - | -15.7% | -13.8% | -19.8% | - | -141.2% | 46.3% | - | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 3.31 | 3.13 | 3.28 | 1.54 | 1.71 | 2.29 | 2.69 | 1.51 | - | - |
| Quick ratio | 3.15 | 3.00 | 3.12 | 1.43 | 1.56 | 2.16 | 2.55 | 1.37 | - | - |
| Cash ratio | 1.64 | 1.62 | 1.87 | 0.45 | 0.24 | 1.17 | 1.54 | 0.71 | - | - |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -5.9x | - | -4.0x | -2.9x | -4.0x | - | -3.9x | -45.6x | - | - |
| Equity multiplier | 5.13 | 4.63 | 4.49 | 5.25 | 4.73 | 16.44 | 18.09 | -0.72 | - | - |
| Liabilities / Assets | 0.80 | 0.78 | 0.78 | 0.81 | 0.79 | 0.94 | 0.94 | 0.97 | - | - |
| Efficiency | ||||||||||
| Asset turnover | 0.16 | - | 0.15 | 0.19 | 0.09 | - | 0.19 | 0.19 | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | 324d | - | 310d | 309d | 657d | - | 294d | 260d | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 0.0x | - | 0.0x | 0.0x | 0.0x | - | 0.2x | - | - | - |
| P / S | 0.0x | - | 0.0x | 0.0x | 0.0x | - | 0.1x | 0.0x | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 138.7% | - | 84.7% | 89.6% | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -59.0% | - | -13.8% | 88.4% | - | - | - | - | - | - |
| Net income growth (YoY) | -94.5% | - | -5.5% | 92.2% | - | - | - | - | - | - |
| EPS growth (YoY) | 51.7% | - | 0.0% | 96.4% | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | 24.2% | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 27.7% | 772.1% | 845.2% | - | - | - | - | - | - | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$2.54B totalDiagnostics$955.38M · 37.6%
Clinical Order$884.50M · 34.8%
Data And Applications$316.41M · 12.4%
Insights Product$257.70M · 10.1%
Genomics Product$70.90M · 2.8%
Trials Product$38.50M · 1.5%
AIApplications$20.10M · 0.8%
Peer comparison
Same SIC group: Services-Computer Programming, Data Processing, Etc.
Comparing Tempus AI against the 5 most active filers in the same SIC group.